Clazakizumab

Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6.[1] Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect.[2]

Clazakizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL6
Clinical data
Other namesALD518, BMS-945429
Routes of
administration		infusion
ATC code
  • none
Legal status
Legal status
  • investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6426H9972N1724O2032S42
Molar mass145239.02 g·mol−1

See also

References
  1. Handbook of Therapeutic Antibodies, Volume 2. Wiley Blackwell. 2007. p. 987. ISBN 9783527329373. Retrieved January 23, 2017.
  2. Mease PJ, Gottlieb AB, et al. (September 2016). "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis". Arthritis Rheumatol. 68 (9): 2163–73. doi:10.1002/art.39700. PMID 27059799. S2CID 3644962.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.